This renewed interest in DB presented Tarsus with an opportunity to reup its efforts to combat a pressing yet often overlooked health condition.

Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares ...